EDG-5506 is a medication being studied to see how it affects people with Becker Muscular Dystrophy, a condition that causes muscle weakness. The trial is looking at how safe the medication is, how it moves through the body, and how it might help improve muscle function. Researchers are also checking if it can change certain markers in the blood that are linked to muscle damage.

Sevasemten is another medication being tested in this trial. It is being studied to understand its safety and how well people with Becker Muscular Dystrophy can tolerate it. The trial is also examining if sevasemten can lower levels of a specific enzyme in the blood called creatine kinase, which is often higher in people with muscle damage. The study includes both adults and adolescents to see how the medication works in different age groups.

Becker Muscular Dystrophy (BMD) – Becker Muscular Dystrophy is a genetic disorder characterized by progressive muscle weakness and wasting. It primarily affects the skeletal muscles, which are responsible for movement, and the heart muscle. The disease is caused by mutations in the dystrophin gene, leading to insufficient production of the dystrophin protein, which is crucial for muscle function. Symptoms often begin in adolescence or early adulthood and include difficulty walking, muscle cramps, and fatigue. As the disease progresses, individuals may experience increased difficulty with mobility and may require assistance with walking. The progression of muscle weakness can vary significantly among individuals with BMD.